Aggressive behavior of mental retardates is a frequent problem which semiological description is very polymorphic. Some psychiatric etiologies are listed, and then the different aspects of idiopathic aggressive behavior are described. These aspects give guidelines for more specific treatments which are further reviewed. Preferential indications and side effects are described for each in a way to suggest a therapeutic strategy. At the end, legal aspects involved are briefly exposed.
References
1.
CytrinL., LourieR.S.Mental retardation. In: FreedmanA.M., KaplanH.I., SadockB.J., eds. Comprehensive textbook of psychiatry, second edition.Baltimore: Maryland,1985: 1158–1197.
2.
BatesW.J., SmeltzerD.J., ArnoczkyS.M.Appropriate and inappropriate use of psychotherapeutic medications for institutionalized mentally retarded persons.Am J Ment Def1986; 90(4): 363–370.
3.
GlaserB.A., MorreauL.E.Effects of interdisciplinary team review on the use of antipsychotic agents with severely and profoundly mentally retarded persons.Am J Ment Def1986; 90(4): 371–379.
4.
Accreditation Council for Services for Mentally Retarded and Other Developmentally Disabled Persons (ACSMRDD).Standards for services for developmentally disabled individuals, revised edition.Washington, D.C.: ACSMRDD, 1980.
5.
KirmanB.Drug therapy in mental handicap.Br J Psychiatry1975; 127: 545–549.
6.
BurgioL.D., PageT.J., CapriottiR.M.Clinical behavioral pharmacology: methods for evaluating medications and contingency management.J App Behav Anal1985; 18(1): 45–59.
7.
DeutschS.E.Managing behavior in mentally retarded residential populations.Hosp Community Psychiatry1986; 37(3): 221–222.
8.
GualtieriC.T., BreuningS.E., SchroederS.R.Tardive dyskinesia in mentally retarded children, adolescents, and young adults: North Carolina and Michigan Studies.Psychopharmacol Bull1982; 18(1): 62–65.
9.
YudofskyS., WilliamsD., GormanJ.Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndromes.Am J Psychiatry1981; 138(2): 218–220.
10.
ReidA.H., BallingerB.R., HeatherB.B.Behavioural syndromes identified by cluster analysis in a sample of 100 severely and profoundly retarded adults.Psychol Med1978; 8: 399–412.
11.
PueschelS.M., RyndersJ.E., eds. Down syndrome: advances in biomedicine and behavioral sciences.Cambridge: Ware Press, 1982.
CampbellM., FishB., KoreinJ.Lithium and chlorpromazine: a controlled crossover study of hyperactive severely disturbed young children.J Autism Child Schizo1972; 2(3): 234–263.
14.
LipmanR.S.The use of pharmacological agents in residential facilities for the retarded. In: MenolascinoF., ed. Psychiatric approaches to mental retardation.New York: Basic Books,1970: 387–397.
15.
SpragueR.L.Overview of psychopharmacology for the retarded in the United States. In: MitlerP., ed. Research to practice in mental retardation – biomedical aspects, Vol. 3.Baltimore: University Park Press,1977: 199–202.
16.
BreuningS.E.An applied dose-response curve of thioridazine with the mentally retarded: aggressive, self-stimulatory, intellectual, and workshop behaviors: a preliminary report.Psychopharmacol Bull1982; 18(1): 57–59.
17.
GualtieriC.T., LeflerW.H., GuimondM.Corneal and lenticular opacities in mentally retarded young adults treated with thioridazine and chlorpromazine.Am J Psychiatry1982; 139(9): 1178–1180.
18.
BreuningS.E., FergusonD.G., DavidsonN.A.Effects of thioridazine on the intellectual performance of mentally retarded drug responders and nonresponders.Arch Gen Psychiatry1983; 40: 309–313.
19.
NeppeV.M.Carbamazepine for the violent psychiatric patient.Lancet1982; ii: 334.
20.
ReidA.H., NaylorG.J., KayD.S.G.A double-blind, placebo controlled, crossover trial of carbamazepine in overactive, severely mentally handicapped patients.Psychol Med1981; 11: 109–113.
GoetzlU., GrunbergF., BerkowitzB.Lithium carbonate in the management of hyperactive aggressive behavior of the mentally retarded.Compr Psychiatry1977; 18(6): 599–606.
SheardM.M., MariniJ.L., BridgesC.I.The effect of lithium on impulsive aggressive behavior in man.Am J Psychiatry1976; 133(12): 1609–1613.
25.
TyrerS.P., WalshA., EdwardsD.E.Factors associated with a good response to lithium in aggressive mentally handicapped subjects.Prog Neuro-Psychopharmacol Biol Psychiatry1984; 8: 751–755.
26.
RapportM.D., MurphyH.A., BaileyJ.S.Ritalin vs. response cost in the control of hyperactive children: a within-subject comparison.J Appl Behav Anal1982; 15(2): 205–216.
27.
WalkerM.K.Stimulants drugs. In: BreuningS.E., PolingA.D., eds. Drugs and mental retardation.Springfield, Ill.: Charles C. Thomas,1982: 235–267.
28.
SchreierM.A.Use of propranolol in the treatment of post-encephalitic psychosis.Am J Psychiatry1979; 136: 840–841.
29.
DeutschS.I.Rationale for the administration of opiate antagonists in treating infantile autism.Am J Ment Def1986; 90(6): 631–635.
30.
WeizmanR., WeizmanA., TyanoS.Humoral-endorphin blood levels in autistic, schizophrenic and healthy subjects.Psychopharmacology1986; 82: 368–370.
31.
SlawsonP.F.Psychiatric malpractice: the California experience.Am J Psychiatry1979; 136(5): 650–654.
32.
Centerbury vs Spence. 464 F 2d 772 (D.C. Dir.), 1972.
33.
SlowenkoR.On the legal aspects of tardive dyskinesia.J Psychiatry Law1979; 3: 295–329.
